Interferon-modulated vaccines against HIV
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3DP2DA051912-01S2
Grant search
Key facts
Disease
N/A
Start & end year
20202024Known Financial Commitments (USD)
$81,547Funder
National Institutes of Health (NIH)Principal Investigator
ASST PROFESSOR Pablo PenalozaResearch Location
United States of AmericaLead Research Institution
NORTHWESTERN UNIVERSITY AT CHICAGOResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Disabled persons
Occupations of Interest
Unspecified
Abstract
Project Summary The main goal of the parent grant is to develop interferon-modulated vaccines against HIV. The proposed research will follow up on the same unifying concept of our parent DP2 grant, but in addition, it will consider the effect of boosting with a heterologous vaccine. Bakare has observed that boosting with a heterologous vaccine regimen enhances the efficacy of vaccines (manuscript in preparation). The preliminary data shown below is with SARS-CoV-2 vaccines, but it demonstrates a potentially novel and universal strategy to improve viral vaccines against HIV and other infectious agents that affect PWID. Improving vaccine efficacy is also critical to improve the lives of PWID.